AI Insight
Researchers have genetically engineered probiotic bacteria to infiltrate pancreatic tumors, where they activate cancer-fighting immune cells and inhibit tumor growth in animal models. The engineered bacteria demonstrated enhanced effectiveness when used in combination with existing cancer treatments including chemotherapy, radiation therapy, and immunotherapy. This approach essentially converts beneficial bacteria into microscopic drug delivery vehicles that can target tumors directly.
Why it matters
Pancreatic cancer is notoriously difficult to treat due to poor drug penetration into tumors and limited treatment options. This bacterial delivery system could potentially improve outcomes by enhancing the effectiveness of existing therapies and accessing hard-to-reach tumor sites that conventional drugs struggle to penetrate.
Understand the Science
Engineered probiotic bacteria were able to infiltrate pancreatic tumors, stimulate cancer-fighting immune cells, and slow tumor growth in animal studies. Even more strikingly, the treatment worked better when combined with chemotherapy, radiation, or immunotherapy.
Source: Scientists turn probiotic bacteria into tiny drug factories for pancreatic cancer